NovaDel Announces Update to Agreement with Amherst Pharmaceuticals
Business Wire - Fri Jan 30, 10:31AM CST
As previously reported, NovaDel Pharma, Inc. (NVDL.PK) has sold its remaining assets, which consisted of the ZolpiMist(R) NDA, a license agreement and related global intellectual property to Amherst Pharmaceuticals, LLC, in exchange for assumption of approximately $2.2 million in fees owed to the FDA in relation to ZolpiMist. As of this date, Amherst has not paid or entered into an agreement to pay the FDA the amount owed.
NovaDel Announces the Sale of Its ZolpiMist(R) New Drug Application, License and Intellectual Property to Amherst Pharmaceuticals, LLC
Business Wire - Mon Sep 22, 7:30AM CDT
NovaDel Pharma Inc. (NVDL.PK) has sold its ZolpiMist(R) New Drug Application to Amherst Pharmaceuticals, LLC. The transaction also includes the NovaDel patents and trademarks covered by NovaDel's license agreement with ECR Pharmaceuticals Co., Inc. for US rights to ZolpiMist as well as the license agreement itself. Also included in the transaction are the international patents and trademarks for ZolpiMist.